(topiramate) has been prescribed off-label as a Migraine preventive for several
years now. During that time, clinical trials were being conducted to gain FDA
approval of Topamax for this purpose. Off-label prescribing is quite common. In
fact, Topamax is only the second medication to be approved for Migraine
prophylaxis, yet there are over 100 medications being used for that purpose.
PRESS RELEASE: RARITAN, NJ, AUGUST 12, 2004
There is new hope for the millions of Americans who suffer from frequent or
severe migraines. The U.S. Food and Drug Administration (FDA) has approved
TOPAMAX ® (topiramate) Tablets and TOPAMAX ® (topiramate capsules) Sprinkle
Capsules for the prophylaxis (prevention) of migraine headaches in adults . In
clinical studies with TOPAMAX, many people with migraines experienced
significantly fewer attacks, enabling them to help manage their condition.
Clinical trials found that patients receiving the recommended daily dose of
TOPAMAX experienced a significant reduction in monthly migraine attacks,
compared with placebo.
Migraines are a chronic, debilitating condition characterized by sharp throbbing
pain on one side of the head, nausea or vomiting, visual disturbances, and/or
sensitivity to noise and light. Approximately 14 million* Americans suffer from
frequent or severe migraines. Many prescription migraine medicines currently
available are taken to treat migraines at the start of an attack. For many
people with frequent or severe migraines, this approach may not be enough. These
patients may be candidates for treatment that may reduce the frequency of their
"Many people who suffer from frequent or severe migraines may benefit from
preventive therapy," said Dr. Elizabeth Loder, Assistant Professor of Medicine,
Harvard Medical School Headache Management Program, Spaulding Rehabilitation
Hospital, Boston, MA. "For people who experience frequent migraine attacks,
TOPAMAX may have a significant impact by helping to reduce how often they
According to the National Headache Foundation (NHF), a leading advocacy
organization, people with migraines are often forced to cope with their attacks.
While some retreat and wait out an attack, many attempt to endure them,
struggling through even the simplest tasks such as completing household chores.
"I work and have a family to take care of so having fewer migraines is very
important to me," explained Sandra Bryan, a TOPAMAX clinical trial patient.
"Taking TOPAMAX for my migraines reduced the number of migraines I had each
month, allowing more time for the things I wanted to do."
People with migraines should talk to their doctors about the treatment options
that are right for them. Factors to discuss include the frequency and severity
of their migraines; medications they are currently using; how often they are
using their migraine medications; and how well their current migraine
medications are working.
"Many people who may be candidates for migraine prevention are not offered this
as an option," said Dr. Loder. "Physicians are more likely to recommend
appropriate treatment when patients fully discuss their condition."
Topiramate has been approved for migraine prophylaxis in 22 countries worldwide.
TOPAMAX is indicated for the prophylaxis of migraine headaches in adults. The
usefulness of TOPAMAX in the acute treatment of migraine headaches has not been
studied. Like most medicines, TOPAMAX may cause side effects. The most common
side effect is tingling in the extremities. Others include fatigue, loss of
appetite, nausea, taste alteration, diarrhea, cognitive side effects and weight
loss. Serious, as well as minor, side effects have been reported with TOPAMAX.
Please see full U.S. Prescribing Information.
Ortho-McNeil Pharmaceutical, Inc. markets TOPAMAX in the United States. Johnson
& Johnson Pharmaceutical Research & Development (J&JPRD) L.L.C. discovered
TOPAMAX and conducted the research for the new indication. Both Ortho-McNeil and
J&JPRD are wholly owned subsidiaries of Johnson & Johnson. Ortho-McNeil
Pharmaceutical, Inc. markets prescription drugs in the areas of women's health,
infectious disease, central nervous system, pain treatment, urology and migraine
headaches . For more information,
www.topamax.com or call 1-800-682-6532.
* A total of more than 32 million Americans suffer from Migraine disease.
More information about Topamax is available on my About.com web site: